Healthcare | April 02, 2024
Vivity reaches 1 million milestone
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
This acquisition enables MTD to open new, strategic markets
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Subscribe To Our Newsletter & Stay Updated
